These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 18926909)

  • 1. Bacteriophage therapy--cooked goose or phoenix rising?
    Mattey M; Spencer J
    Curr Opin Biotechnol; 2008 Dec; 19(6):608-12. PubMed ID: 18926909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory aspects for translating gene therapy research into the clinic.
    Laurencot CM; Ruppel S
    Methods Mol Biol; 2009; 542():397-421. PubMed ID: 19565915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential.
    Barrow PA; Soothill JS
    Trends Microbiol; 1997 Jul; 5(7):268-71. PubMed ID: 9234508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacteriophage therapy.
    Summers WC
    Annu Rev Microbiol; 2001; 55():437-51. PubMed ID: 11544363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of the Istituto Superiore di Sanità as the competent authority for Phase I trials in the translation of advanced therapies.
    Popoli P; Cometa MF; Fabi F; Meneguz A
    Ann Ist Super Sanita; 2011; 47(1):79-82. PubMed ID: 21430344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers.
    Sinkovics JG; Horvath JC
    Arch Immunol Ther Exp (Warsz); 2008 Dec; 56 Suppl 1():3s-59s. PubMed ID: 19104757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bacteriophage Production in Compliance with Regulatory Requirements.
    Pirnay JP; Merabishvili M; De Vos D; Verbeken G
    Methods Mol Biol; 2024; 2734():89-115. PubMed ID: 38066364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacteriophage therapy: exploiting smaller fleas.
    Deresinski S
    Clin Infect Dis; 2009 Apr; 48(8):1096-101. PubMed ID: 19275495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bacteriophage Production in Compliance with Regulatory Requirements.
    Pirnay JP; Merabishvili M; Van Raemdonck H; De Vos D; Verbeken G
    Methods Mol Biol; 2018; 1693():233-252. PubMed ID: 29119444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk-based assessment applied to QA GLP audits. How to fulfill regulatory requirements while making the best use of our common sense, knowledge, talents, and resources?
    Piton A
    Ann Ist Super Sanita; 2008; 44(4):379-84. PubMed ID: 19352000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of regulated clinical trials in the development of bacteriophage therapeutics.
    Parracho HM; Burrowes BH; Enright MC; McConville ML; Harper DR
    J Mol Genet Med; 2012; 6():279-86. PubMed ID: 22872803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Bacteriophage therapy revisited].
    Kallings LO
    Lakartidningen; 2009 Oct 14-20; 106(42):2708. PubMed ID: 19972672
    [No Abstract]   [Full Text] [Related]  

  • 14. Bacteriophages and their application in food safety.
    García P; Martínez B; Obeso JM; Rodríguez A
    Lett Appl Microbiol; 2008 Dec; 47(6):479-85. PubMed ID: 19120914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Release testing of retroviral vectors and gene-modified cells.
    Nordling D; Kaiser A; Reeves L
    Methods Mol Biol; 2009; 506():265-79. PubMed ID: 19110632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developments in consultancy and training in the GLP arena: 1980 to 2020. A personal view.
    Long D
    Ann Ist Super Sanita; 2008; 44(4):409-16. PubMed ID: 19352006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role for bacteriophages in the preparedness for fighting against pneumonia in the postantibiotic era.
    Luna CM; Bruno D
    Crit Care Med; 2009 Feb; 37(2):779-80. PubMed ID: 19325387
    [No Abstract]   [Full Text] [Related]  

  • 19. The potential of phage therapy in bacterial infections of the eye.
    Górski A; Targońska M; Borysowski J; Weber-Dabrowska B
    Ophthalmologica; 2009; 223(3):162-5. PubMed ID: 19155637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies.
    Muller PY; Brennan FR
    Clin Pharmacol Ther; 2009 Mar; 85(3):247-58. PubMed ID: 19177065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.